Medications for Metastatic Colorectal Carcinoma

5 results

  • avastin

    (bevacizumab)
    Genentech, Inc.
    Avastin is indicated for the treatment of various cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent or recurrent cervical cancer, and advanced epithelial ovarian or peritoneal cancers, often in combination with other chemotherapy agents.

  • braftovi

    (Encorafenib)
    Array BioPharma Inc.
    BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer, all positive for BRAF V600E or V600K mutations. These treatments require combination therapies and FDA-approved testing for mutation detection. Not for wild-type BRAF cancers.

  • vectibix

    (panitumumab)
    Amgen Inc
    Vectibix is indicated for treating metastatic colorectal cancer (mCRC) in adults with wild-type RAS as first-line therapy with FOLFOX or as monotherapy post-chemotherapy progression. It also treats KRAS G12C-mutated mCRC in combination with sotorasib after prior chemotherapy. Not for RAS-mutant mCRC unless combined with sotorasib.

  • zaltrap

    (ziv-aflibercept)
    sanofi-aventis U.S. LLC
    ZALTRAP, combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after treatment with an oxaliplatin-containing regimen.

  • zirabev

    (bevacizumab-bvzr)
    Pfizer Laboratories Div Pfizer Inc
    ZIRABEV is indicated for treating metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent/recurrent/metastatic cervical cancer, and advanced epithelial ovarian/fallopian tube/peritoneal cancer, often in combination with other chemotherapy agents.